This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Inogen (INGN) Stock Loses 9.2% After Delivering Loss in Q3
by Zacks Equity Research
Inogen (INGN) saw revenue decline within its Sales segment in Q3
PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q4
by Zacks Equity Research
Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in the fiscal fourth quarter.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) rides high on the launch of the Axeos imaging system in the third quarter.
Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume
Fresenius Medical (FMS) Stock Gains 5.6% on Q3 Earnings Beat
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter earnings benefit from stable segmental performance.
Change Healthcare (CHNG) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal second-quarter results benefit from solid performance in the Network Solutions segment.
Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results reflect strong segmental performance.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.
Surmodics (SRDX) Reports Q4 Loss, Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.
Pacific Biosciences (PACB) Loses 4.1% Post Reporting Q3 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter.
Avanos Medical (AVNS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continued to gain from core Chronic Care segment in the third quarter.
McKesson (MCK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter 2021 results benefit from strong segmental performance.
Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates
by Zacks Equity Research
Accuray (ARAY) registered growth in Service revenues in Q1.
OPKO Health (OPK) Loses 16.2% Despite In-Line Q3 Earnings
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.
Allscripts (MDRX) Declines 1.9% Despite Q3 Earnings Beat
by Zacks Equity Research
Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during the third quarter.
Integer Holdings (ITGR) Q3 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect weak segmental performance.
Stryker (SYK) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong segmental performance.
Merit Medical (MMSI) Rallies 4.8% Post Q3 Earnings Beat
by Zacks Equity Research
Merit Medical (MMSI) reported growth in revenues at Cardiovascular segment in the third quarter.
DaVita (DVA) Earnings Beat Estimates in Q3, Revenues Miss
by Zacks Equity Research
DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.
Omnicell (OMCL) Q3 Earnings Top, Pre-COVID-19 View Reinstated
by Zacks Equity Research
Omnicell's (OMCL) Service and other revenues improve in Q3 despite the pandemic-led business challenges.
AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Globus Medical (GMED) Q3 Earnings Beat, U.S. Business Strong
by Zacks Equity Research
Globus Medical's (GMED) spinal implant business performance varies by region in Q3.
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect strong performance across six of its business units.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
ABIOMED's (ABMD) international Impella revenues improved in Q2.